+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism



Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism



Bmc Medicine 11: 233



Perhaps no greater challenge exists for public health, patient safety, and shared global health security, than fake/falsified/fraudulent, poor quality unregulated drugs, also commonly known as "counterfeit medicines", now endemic in the global drug supply chain. Counterfeit medicines are prevalent everywhere, from traditional healthcare settings to unregulated sectors, including the Internet. These dangerous medicines are expanding in both therapeutic and geographic scope, threatening patient lives, leading to antimicrobial resistance, and profiting criminal actors. Despite clear global public health threats, surveillance for counterfeit medicines remains extremely limited, with available data pointing to an increasing global criminal trade that has yet to be addressed appropriately. Efforts by a variety of public and private sector entities, national governments, and international organizations have made inroads in combating this illicit trade, but are stymied by ineffectual governance and divergent interests. Specifically, recent efforts by the World Health Organization, the primary international public health agency, have failed to adequately incorporate the broad array of stakeholders necessary to combat the problem. This has left the task of combating counterfeit medicines to other organizations such as UN Office of Drugs and Crime and Interpol in order to fill this policy gap. To address the current failure of the international community to mobilize against the worldwide counterfeit medicines threat, we recommend the establishment of an enhanced global health governance trilateral mechanism between WHO, UNODC, and Interpol to leverage the respective strengths and resources of these organizations. This would allow these critical organizations, already engaged in the fight against counterfeit medicines, to focus on and coordinate their respective domains of transnational crime prevention, public health, and law enforcement field operations. Specifically, by forming a global partnership that focuses on combating the transnational criminal and patient safety elements of this pre-eminent global health problem, there can be progress against counterfeit drugs and their purveyors.

(PDF emailed within 0-6 h: $19.90)

Accession: 053752954

Download citation: RISBibTeXText

PMID: 24228892

DOI: 10.1186/1741-7015-11-233


Related references

Combating counterfeit medicines and illicit trade in tobacco products: minefields in global health governance. Journal of Law, Medicine and Ethics 40(2): 326-347, 2012

Improving Access to Essential Medicines: How Health Concerns can be Prioritised in the Global Governance System. Public Health Ethics 1(2): 83-88, 2009

Addressing global health governance challenges through a new mechanism: the proposal for a Committee C of the World Health Assembly. Journal of Law, Medicine and Ethics 38(3): 550-563, 2011

Nonbinding Legal Instruments in Governance for Global Health: Lessons from the Global AIDS Reporting Mechanism. Journal of Law, Medicine and Ethics 42(1): 72-87, 2016

Leveraging non-binding instruments for global health governance: reflections from the Global AIDS Reporting Mechanism for WHO reform. Public Health 128(2): 151-160, 2014

Governance within the World Health Assembly: a 13-year analysis of WHO Member States' contribution to global health governance. Health Policy 119(3): 395-404, 2016

Public health issues with counterfeit medicines. Clinical Medicine 9(1): 63-64, 2009

From the combat medic to the forward surgical team: the Madigan model for improving trauma readiness of brigade combat teams fighting the Global War on Terror. Journal of Surgical Research 138(1): 25-31, 2007

Viewpoint: Counterfeit medicines and substandard medicines: Different problems requiring different solutions. Journal of Public Health Policy 36(4): 384-389, 2016

The Lancet-University of Oslo Commission on Global Governance for Health, in collaboration with the Harvard Global Health Institute. Lancet 378(9803): 1612-1613, 2011

Making sense of the global health crisis: policy narratives, conflict, and global health governance. Journal of Health Politics, Policy and Law 37(2): 253-295, 2012

Non-communicable diseases and global health governance: enhancing global processes to improve health development. Globalization and Health 3: 2, 2007

Right to health encompasses right to access essential generic medicines: challenging the 2008 Anti-Counterfeit Act in Kenya. Health and Human Rights 16(2): E96-E104, 2015

Fake medicines are undermining global efforts to combat infectious disease, says US journal. Bmj 350: H2137, 2015